Liquidia (NASDAQ:LQDA) General Counsel Russell Schundler Sells 14,738 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 14,738 shares of Liquidia stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $1,053,914.38. Following the sale, the general counsel directly owned 605,962 shares in the company, valued at $43,332,342.62. The trade was a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 7.4%

Shares of LQDA stock opened at $76.49 on Wednesday. Liquidia Corporation has a one year low of $14.04 and a one year high of $82.96. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The stock has a fifty day moving average price of $66.37 and a 200 day moving average price of $47.52. The stock has a market cap of $6.80 billion, a P/E ratio of 546.40 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The business’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Analysts predict that Liquidia Corporation will post 3.02 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LQDA. Farallon Capital Management LLC grew its holdings in Liquidia by 1.1% during the 4th quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after acquiring an additional 90,400 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Liquidia by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after acquiring an additional 52,671 shares during the last quarter. Opaleye Management Inc. lifted its position in shares of Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after purchasing an additional 215,000 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares in the last quarter. Finally, Caprock Group LLC grew its stake in shares of Liquidia by 9.3% during the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after purchasing an additional 151,832 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent commentary notes that Liquidia’s Yutrepia has had a strong commercial debut, suggesting early traction in its pulmonary arterial hypertension market opportunity. Can LQDA’s Yutrepia Drive Growth in the Competitive PAH Market?
• Neutral Sentiment: An investor letter from Laughing Water Capital mentioned Liquidia in a broader portfolio update, but did not provide a clear company-specific catalyst. Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
• Negative Sentiment: Multiple insiders, including the CEO, CFO, general counsel, and other executives, sold shares on July 13 in pre-arranged 10b5-1 transactions tied to tax withholding from vesting equity awards. While these sales were planned and not necessarily a bearish signal, the size and breadth of the sales may still pressure investor sentiment. SEC filing – Roger Jeffs sale

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. BTIG Research raised their price target on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Raymond James Financial reaffirmed a “strong-buy” rating and set a $68.00 price objective on shares of Liquidia in a report on Thursday, June 4th. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research note on Monday, May 11th. Finally, HC Wainwright increased their target price on Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, June 5th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).